↓ Skip to main content
Embed badge What is this page?

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

Overview of attention for article published in BMC Cancer, September 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
35 Mendeley

What is this page?

Summary Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Published in
BMC Cancer, September 2012
DOI 10.1186/1471-2407-12-411
Pubmed ID
22985168
Authors

Afsar Ali Mian, Anna Metodieva, Susanne Badura, Mamduh Khateb, Nili Ruimi, Yousef Najajreh, Oliver Gerhard Ottmann, Jamal Mahajna, Martin Ruthardt

Abstract

Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase "escapes" the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 3%
Canada 1 3%
Unknown 33 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 26%
Professor 4 11%
Student > Master 4 11%
Student > Bachelor 4 11%
Student > Ph. D. Student 3 9%
Other 7 20%
Unknown 4 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 9 26%
Medicine and Dentistry 7 20%
Chemistry 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Biochemistry, Genetics and Molecular Biology 3 9%
Other 5 14%
Unknown 5 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2012.
All research outputs
#7,762,244
of 12,372,945 outputs
Outputs from BMC Cancer
#2,226
of 4,558 outputs
Outputs of similar age
#71,872
of 129,610 outputs
Outputs of similar age from BMC Cancer
#4
of 13 outputs
Altmetric has tracked 12,372,945 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,558 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 129,610 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.

This page is provided by Altmetric.